Literature DB >> 30796985

Update on the contraceptive contraindications.

D Serfaty1.   

Abstract

BACKGROUND: The choice of contraceptive methods has considerably increased over recent years. However, all available methods are not appropriate for all women, especially those with medical conditions or individual characteristics in whom any pregnancy, particularly unintended pregnancy, is at higher risk. The safety of contraception is crucial for these women and evidence-based guidance to help healthcare providers choosing a suitable method has been published. The aim of our review is to make an update on the main contraceptive contraindications.
METHODS: The World Health Organisation Medical Eligibility Criteria for Contraceptive Use (WHO-MEC) published in 2015 are referred to throughout this review. The rationale behind the recommendations for women with cardiovascular, rheumatic, neurologic, gynaecological or endocrine disorders was first analysed. The national adaptations of the WHO-MEC, especially the French, British, and American ones, were then scrutinized. MAIN
FINDINGS: Overall, the MECs considered tend to provide the same recommendations. However, there are some noticeable differences that may be useful to know. Hence, for a given condition, differences in categorisation have been noticed where limited or controversial scientific evidence relating to this condition exists, especially regarding hormonal contraceptives. Some medical conditions or characteristics, included in some MECs but not in others, have also been identified.
CONCLUSION: MECs represent valuable tools to help clinicians to prescribe the most acceptable and safe contraceptive method for each individual woman. Although it may be useful to consult different MECs for some complex conditions, prescribers should always bear in mind that these MECs are only guidelines and that their clinical judgment should always prevail.
Copyright © 2019 The Author. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Contraception; Contraindications; Medical eligibility criteria

Mesh:

Substances:

Year:  2019        PMID: 30796985     DOI: 10.1016/j.jogoh.2019.02.006

Source DB:  PubMed          Journal:  J Gynecol Obstet Hum Reprod        ISSN: 2468-7847


  7 in total

Review 1.  Update on Management of Cardiovascular Diseases in Women.

Authors:  Fabiana Lucà; Maurizio Giuseppe Abrignani; Iris Parrini; Stefania Angela Di Fusco; Simona Giubilato; Carmelo Massimiliano Rao; Laura Piccioni; Laura Cipolletta; Bruno Passaretti; Francesco Giallauria; Angelo Leone; Giuseppina Maura Francese; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

2.  Clinical practice guideline of the Interamerican Society of Cardiology on primary prevention of cardiovascular disease in women.

Authors:  Mildren A Del-Sueldo; María A Mendonça-Rivera; Martha B Sánchez-Zambrano; Judith Zilberman; Ana G Múnera-Echeverri; María Paniagua; Lourdes Campos-Alcántara; Claudia Almonte; Amalia Paix-Gonzales; Claudia V Anchique-Santos; Claudine J Coronel; Gabriela Castillo; María G Parra-Machuca; Ivanna Duro; Paola Varletta; Patricia Delgado; Verónica I Volberg; Adriana C Puente-Barragán; Adriana Rodríguez; Aida Rotta-Rotta; Anabela Fernández; Ana C Izeta-Gutiérrez; Ana E Ancona-Vadillo; Analía Aquieri; Andrea Corrales; Andrea Simeone; Bibiana Rubilar; Carolina Artucio; Carolina Pimentel-Fernández; Celi Marques-Santos; Clara Saldarriaga; Christian Chávez; Cristina Cáceres; Dahiana Ibarrola; Daniela Barranco; Edison Muñoz-Ortiz; Edith D Ruiz-Gastelum; Eduardo Bianco; Elena Murguía; Enrique Soto; Fabiola Rodríguez-Caballero; Fanny Otiniano-Costa; Giovanna Valentino; Iris B Rodríguez-Cermeño; Ivan R Rivera; Jairo A Gándara-Ricardo; Jesús A Velásquez-Penagos; Judith Torales; Karina Scavenius; Karen Dueñas-Criado; Laura García; Laura Roballo; Lucía R Kazelian; Macarena Coussirat-Liendo; María C Costa-Almeida; Mariana Drever; Mariela Lujambio; Marildes L Castro; Maritza Rodríguez-Sifuentes; Mónica Acevedo; Mónica Giambruno; Mónica Ramírez; Nancy Gómez; Narcisa Gutiérrez-Castillo; Onelia Greatty; Paola Harwicz; Patricia Notaro; Rocío Falcón; Rosario López; Sady Montefilpo; Sara Ramírez-Flores; Silvina Verdugo; Soledad Murguía; Sonia Constantini; Thais C Vieira; Virginia Michelis; César M Serra
Journal:  Arch Cardiol Mex       Date:  2022

3.  Fertility treatment and oral contraceptive discontinuation for identification of pregnancy planning in routinely collected health data - an application to analgesic and antibiotic utilisation.

Authors:  Sarah Hjorth; Mollie Wood; Fatima Tauqeer; Hedvig Nordeng
Journal:  BMC Pregnancy Childbirth       Date:  2020-11-25       Impact factor: 3.007

4.  Contraception in chronic kidney disease: a best practice position statement by the Kidney and Pregnancy Group of the Italian Society of Nephrology.

Authors:  Rossella Attini; Gianfranca Cabiddu; Benedetta Montersino; Linda Gammaro; Giuseppe Gernone; Gabriella Moroni; Domenico Santoro; Donatella Spotti; Bianca Masturzo; Isabella Bianca Gazzani; Guido Menato; Valentina Donvito; Anna Maria Paoletti; Giorgina Barbara Piccoli
Journal:  J Nephrol       Date:  2020-03-12       Impact factor: 3.902

5.  Provider Attitudes, Preferences, and Practices Regarding Sexual and Reproductive Health for Adolescents and Young Adults With Sickle Cell Disease.

Authors:  Maayan Leroy-Melamed; Seethal Jacob; Marcia L Shew; Traci M Kazmerski
Journal:  J Adolesc Health       Date:  2021-07-20       Impact factor: 5.012

6.  Birth control pills and risk of hypothyroidism: a cross-sectional study of the National Health and Nutrition Examination Survey, 2007-2012.

Authors:  Yuxuan Qiu; Yuanyuan Hu; Zhichao Xing; Qingyu Fu; Jingqiang Zhu; Anping Su
Journal:  BMJ Open       Date:  2021-06-23       Impact factor: 2.692

7.  Arterial Stiffness and Hemodynamics in Young Women: The Effects of Oral Contraceptive Intake and Physical Habits.

Authors:  Carina Enea; Pernelle Laffetas; Aurélien Pichon; Nathalie Delpech
Journal:  Int J Environ Res Public Health       Date:  2021-03-25       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.